Pier Luigi Zinzani

Glofitamab in combination with polatuzumab vedotin demonstrates high and durable efficacy in patients with relapsed/refractory (R/R) large B-cell lymphoma (LBCL) in the second-line (2L) and third-line and later (3L+) settings: A subgroup analysis

Martin Hutchings, Anna Sureda Balarí, Francesc Bosch, Thomas Stauffer Larsen et autres

Abstract Background: Despite recent advances, R/R LBCL remains clinically challenging with poor outcomes and a critical need for effective and durable treatment options, particularly for patients with high-risk characteristics. In this open-label, multicenter, Phase Ib/II study (NCT03533283), glofitamab in combination with polatuzumab …

dk, es, it, il, cn, gb, ch (code pays fourni par la source)

Interim analysis of PRO-MIND: Consistent quality of life in elderly patients with R/R DLBCL receiving tafasitamab and lenalidomide

Pier Luigi Zinzani, Maria Christina Cox, Flaminia Bellisario, Andrea Bernardelli et autres

Abstract Background: While there is increasing real-world (RW) evidence on the tafasitamab-lenalidomide (TL) combination in patients (pts) with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL), data regarding its impact on health-related quality of life (HRQoL) are still lacking. HRQoL is a crucial …

it, jp (code pays fourni par la source)

ZUMA-25 preliminary analysis: A Phase 2 study of brexucabtagene autoleucel (brexu-cel) in patients (Pts) with relapsed/refractory (R/R) burkitt lymphoma (BL), substudy C

Suzanne van Dorp, Georg Stüssi, Anna Maria Frustaci, Ian W. Flinn et autres

Abstract Introduction: Brexu-cel is an autologous anti-CD19 CAR T-cell therapy approved for adults with R/R MCL and R/R B-ALL. BL is a rare, highly aggressive B-cell malignancy characterized by translocation of the MYC oncogene. Pts with R/R BL have limited treatment options …

nl, ch, it, us, de, es, at, fr (code pays fourni par la source)

Monoclonal and polyclonal circulating plasma cells (CPCs) are linked to disease spread in multiple myeloma

Ilaria Vigliotta, Alessia Varacalli, Marco Talarico, Vincenza Solli et autres

Abstract Multiple myeloma (MM) is a hematological malignancy characterized by clonal expansion of plasma cells (PC) in the bone marrow (BM), with occasional presence in peripheral blood (PB) as circulating plasma cells (CPCs). Over the past decade, patient (pt) outcomes in MM …

it (code pays fourni par la source)

The prognostic value of patient-reported fatigue for survival in patients with aggressive B-cell lymphomas treated with CAR T-cell therapy

Fabio Efficace, Pier Luigi Zinzani, Francesca Bonifazi, Ilaria Cutini et autres

Abstract Background Chimeric antigen receptor (CAR) T-cell therapy is a valuable treatment option for patients with aggressive B-cell lymphomas. Predicting survival is critical to better identify patients at risk and some pre-infusion clinical and laboratory prognostic factors have already been identified. However, …

it (code pays fourni par la source)

A patchy prognosis: identification of prognostic factors associated with significant reduction in survival of early-stage Mycosis Fungoides patients

Julia Jane Scarisbrick, Sean J Whittaker, Christiane Querfeld, Maarten H. Vermeer et autres

IBCL-419: A Meta-Analysis Investigating Response Rates of Continuous Bruton Tyrosine Kinase Inhibitor (BTKi) Monotherapies in the Treatment of B-Cell Lymphoma (BCL)

Pier Luigi Zinzani, Rhys Williams, Xue Mei, Binod Neupane et autres

it, py (code pays fourni par la source)

ORAL ABSTRACT: ABCL-777 Initial Results From LOTIS-7: A Phase 1b Study of Loncastuximab Tesirine Plus Glofitamab in Patients With Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)

Juan Pablo Alderuccio, Craig Y. Okada, Gilles Crochet, Emily C. Ayers et autres

POSTER: ABCL-777 Initial Results From LOTIS-7: A Phase 1b Study of Loncastuximab Tesirine Plus Glofitamab in Patients With Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)

Juan Pablo Alderuccio, Craig Y. Okada, Gilles Crochet, Emily C. Ayers et autres

us, be, it, ch (code pays fourni par la source)

ABCL-777: Initial Results From LOTIS-7: A Phase 1b Study of Loncastuximab Tesirine Plus Glofitamab in Patients With Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)

Juan Pablo Alderuccio, Craig Y. Okada, Gilles Crochet, Emily C. Ayers et autres

Odronextamab monotherapy in patients with relapsed/refractory diffuse large B cell lymphoma: primary efficacy and safety analysis in phase 2 ELM-2 trial

Won Seog Kim, Tae Min Kim, Seok‐Goo Cho, Isidro Jarque et autres

The phase 2, multicohort, ongoing ELM-2 study evaluates odronextamab, a CD20×CD3 bispecific antibody, in patients with relapsed/refractory (R/R) B cell non-Hodgkin lymphoma after ≥2 lines of therapy. Here primary analysis of the diffuse large B cell lymphoma (DLBCL) cohort is reported. Patients …

kr, es, pl, sg, au, cn, fr, tw, us, ca, de, it, jp (code pays fourni par la source)

Cutaneous T-cell lymphomas: a real-life experience of anticipated use of mogamulizumab in Italy

Marco Ardigò, Leonardo Flenghi, Adalberto Ibatici, Cesare Massone et autres

Mogamulizumab is a humanized monoclonal antibody with enhanced antibody-dependent cell-mediated cytotoxicity that targets chemokine receptor type. Several clinical trials and real-life experiences confirmed the efficacy and safety profiles of mogamulizumab as second-line therapy and beyond, and the biochemical- and dermatology-specific quality of …

it (code pays fourni par la source)